Effect of Fucoidan Administration on Insulin Secretion and Insulin Resistance in Overweight or Obese Adults

Hernández-Corona, Diana Mercedes; Martı́nez-Abundis, Esperanza; González-Ortı́z, Manuel

doi:10.1089/jmf.2013.0053

Cited by 65 publications

(65 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is an important consideration since human work supports the concept for fucoidan worsening insulin resistance (Hernández‐Corona et al. ). In fact, a daily oral dose of 500 mg of fucoidan to overweight/obese humans for 3 months increased both insulin levels and a marker of insulin resistance (HOMA‐IR).…”

Section: Discussionmentioning

confidence: 99%

“…Sulphated polysaccharides have many potential cellular targets that depend on the dose-response relationships and, to the best of our knowledge, no ligand-receptor relationship has been established for the actions of fucoidan on blood glucose. This is an important consideration since human work supports the concept for fucoidan worsening insulin resistance (Hern andez-Corona et al 2014). In fact, a daily oral dose of 500 mg of fucoidan to overweight/obese humans for 3 months increased both insulin levels and a marker of insulin resistance (HOMA-IR).…”

Section: Discussionmentioning

confidence: 99%

“…This fucoidan‐mediated deterioration of insulin resistance in obese humans occurred despite a reduction in blood pressure and lowering of LDL cholesterol (Hernández‐Corona et al. ). This warrants investigation of the role of MSR1 in glucose metabolism versus cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice

Cavallari¹,

Anhê²,

Foley³

et al. 2018

Physiol Rep

View full text Add to dashboard Cite

Immune components can bridge inflammatory triggers to metabolic dysfunction. Scavenger receptors sense lipoproteins, but it is not clear how different scavenger receptors alter carbohydrate metabolism during obesity. Macrophage scavenger receptor 1 (MSR1) and macrophage receptor with collagenous structure (MARCO) are scavenger receptors that have been implicated in lipoprotein metabolism and cardiovascular disease. We assessed glucose control, tissue‐specific insulin sensitivity, and inflammation in Msr1‐ and Marco‐deficient mice fed with obesogenic diets. Compared to wild‐type (WT) mice, Msr1 −/− mice had worse blood glucose control that was only revealed after diet‐induced obesity, not in lean mice. Obese Msr1 −/− mice had worse insulin‐stimulated glucose uptake in the adipose tissue, which occurred in the absence of overt differences in adipose inflammation compared to obese WT mice. Msr1 deletion worsened dysglycemia independently from bacterial cell wall insulin sensitizers, such as muramyl dipeptide. MARCO was dispensable for glycemic control in obese mice. Oral administration of the polysaccharide fucoidan worsened glucose control in obese WT mice, but fucoidan had no effect on glycemia in obese Msr1 −/− mice. Therefore, MSR1 is a scavenger receptor responsible for changes in glucose control in response to the environmental ligand fucoidan. Given the interest in dietary supplements and natural products reducing inflammation or insulin resistance in metabolic disease during obesity, our results highlight the importance of understanding which ligand–receptor relationships promote versus those that protect against metabolic disease factors. Our results show that ligand or gene targeting of MSR1 exacerbates insulin resistance in obese mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice

Cavallari¹,

Anhê²,

Foley³

et al. 2018

Physiol Rep

View full text Add to dashboard Cite

show abstract

“…A randomized, double-blind, placebo-controlled clinical trial on fucoidans was conducted on 25 obese or overweight human subjects [84]. Fucoidan administration during the three-month period resulted in decreased diastolic blood pressure and LDL-cholesterol levels, increased insulin secretion and insulin resistance in the overweight or obese adults.…”

Section: Algal Compounds With Anti-obesity Effectsmentioning

confidence: 99%

Marine Algae as a Potential Source for Anti-Obesity Agents

2016

View full text Add to dashboard Cite

Obesity is a major epidemic that poses a worldwide threat to human health, as it is also associated with metabolic syndrome, type 2 diabetes and cardiovascular disease. Therapeutic intervention through weight loss drugs, accompanied by diet and exercise, is one of the options for the treatment and management of obesity. However, the only approved anti-obesity drug currently available in the market is orlistat, a synthetic inhibitor of pancreatic lipase. Other anti-obesity drugs are still being evaluated at different stages of clinical trials, while some have been withdrawn due to their severe adverse effects. Thus, there is a need to look for new anti-obesity agents, especially from biological sources. Marine algae, especially seaweeds are a promising source of anti-obesity agents. Four major bioactive compounds from seaweeds which have the potential as anti-obesity agents are fucoxanthin, alginates, fucoidans and phlorotannins. The anti-obesity effects of such compounds are due to several mechanisms, which include the inhibition of lipid absorption and metabolism (e.g., fucoxanthin and fucoidans), effect on satiety feeling (e.g., alginates), and inhibition of adipocyte differentiation (e.g., fucoxanthin). Further studies, especially testing bioactive compounds in long-term human trials are required before any new anti-obesity drugs based on algal products can be developed.

show abstract

“…Due to its anti-oxidative, anticancer, and anti-inflammatory activities, it has been suggested to be important in cancer and inflammation (8). In addition, fucoidan has been reported to be associated with insulin resistance (9); however, the effects of fucoidan on insulin stimulation and pancreatic protection in spontaneous diabetes have not been investigated. Insulin is a key regulator of body glucose levels (10); therefore, the present study aimed to determine whether fucoidan can stimulate insulin secretion and protect pancreatic function.…”

Section: Introductionmentioning

confidence: 99%

Effects of fucoidan on insulin stimulation and pancreatic protection via the cAMP signaling pathway in vivo and in vitro

Jiang

Mao

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Diabetes is a global disease, in which pancreatic dysfunction is an important pathological process. In previous years, interest in the biological activities of seaweed has increased. Fucoidan is an extract of the seaweed Fucus vesiculosus, which has been widely investigated. The present study aimed to determine the effects of fucoidan on insulin stimulation and pancreatic protection in vivo and in vitro. Goto‑Kakizaki (GK) rats were provided with free access to standard food, with or without fucoidan, for 13 weeks, following which the body weights, and blood glucose and serum insulin levels of the rats were measured. Wistar rats were used as a control. In addition, the RIN‑5F rat insulin‑secreting cell line was treated with fucoidan in high glucose conditions, following which the dose‑dependent and time‑dependent effects of fucoidan were determined, and the concentration of insulin was measured. Glybenclamide was used as a positive control. In vivo, the body weight and serum insulin levels decreased, whereas blood glucose levels increased significantly in the GK rats, compared with the Wistar control rats. Although, fucoidan did not improve changes in body weight, the increased blood glucose levels were reduced and the decreased serum insulin levels were increased in the GK rats following oral administration of fucoidan. In vitro, fucoidan did not exhibit significant cytotoxicity towards the RIN‑5F cells, and the insulin secretion increased significantly in a dose‑ and time‑dependent manner. Treatment with amylin, an islet amyloid polypeptide and glybenclamide inhibitor, did not inhibit the stimulatory activity of fucoidan. The results of the present study also demonstrated that the concentration of cyclic adenosine monophosphate (cAMP) was significantly increased in the fucoidan‑treated RIN‑5F cells, and this increase was dose‑ and time‑dependent. In addition, treatment with a phosphodiesterase inhibitor, which decreases the degradation of cAMP, significantly increased fucoidan‑induced insulin secretion, whereas treatment with an adenylyl cyclase inhibitor, which decreases the generation of cAMP, significantly decreased fucoidan‑induced insulin secretion. In conclusion, these data indicated that fucoidan may stimulate insulin secretion and provide pancreatic protection via the cAMP signaling pathway, in vivo and in vitro.

show abstract

Effect of Fucoidan Administration on Insulin Secretion and Insulin Resistance in Overweight or Obese Adults

Cited by 65 publications

References 6 publications

Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice

Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice

Marine Algae as a Potential Source for Anti-Obesity Agents

Effects of fucoidan on insulin stimulation and pancreatic protection via the cAMP signaling pathway in vivo and in vitro

Contact Info

Product

Resources

About